Scientists have had a major breakthrough in understanding how aggressive skin and oral cancers grow, spread, and resist ...

A potential target for experimental drugs that block PRMT5—a naturally occurring enzyme some tumors rely more on for survival—has been identified by researchers with the Fralin Biomedical Research ...

Drug delivery combination products play an important role in delivering medications to patients by enabling safe, effective, and reliable administration of the intended dose. Examples include ready-to ...

Combination strategies and switching therapies offer alternatives when monotherapy for alopecia areata is ineffective, addressing limited efficacy and side effects of traditional treatments. JAK ...

Peter Mac researchers have discovered a powerful new drug combination that could offer hope to children and adults with certain subtypes of acute myeloid leukemia (AML). The treatment works by using a ...

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and ...

Nerandomilast (PDE4B inhibitor) joined nintedanib and pirfenidone as FDA-approved options, with each demonstrating reduced FVC decline rates in IPF. Clinical benefit is clearest in progressive ...

AstraZeneca’s equity investment in Summit Therapeutics comes with plans for clinical trial collaborations. The deal brings ...

It is becoming increasingly common for pharma and biotech companies to have a clearly defined strategy to transition their drug from a vial into a combination product format to enhance patient ...

Using CRISPR gene editing, Kathleen Mulvaney (center), an assistant professor with the Fralin Biomedical Research Institute, revealed a combination of therapies that showed promise in treating cancer ...